sacituzumab govitecan

  •   George Lundberg, MD

    Recurrent triple-negative breast cancer is particularly difficult to treat. As reported by Cancer Network, the U.S. Food and Drug Administration (FDA) has now approved the drug sacituzumab govitecan (Trodelvy) for treating people with this disease, depending on their stage and treatment history.


  •   Emma Shtivelman, PhD


    An experimental drug has shown promise in extending the lives of women suffering from a particularly aggressive and deadly type of breast cancer, according to the results of a phase 2 trial.

    “Right now, the standard treatment of chemotherapy for metastatic triple-negative breast cancer has not been very effective. That might change with the new drug, called sacituzumab govitecan, which combines an antibody with a chemotherapy drug to better target cancer cells.”

    Go to full article published by U.S. News on Feb 20, 2019.

    If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.